BioCryst Pharmaceuticals Inc Long-term Investment Intensity
BioCryst Pharmaceuticals Inc long-term investment intensity. BioCryst Pharmaceuticals Inc (BCRX) has a Long-term Investment Intensity of 11.9% as of December 2025. Long-term investments of $61.16 Million represent 11.9% of total assets of $514.16 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See working capital position of BioCryst Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Long-term Investment Intensity of BioCryst Pharmaceuticals Inc (2011–2025)
Long-term investment intensity of BioCryst Pharmaceuticals Inc from 2011 to 2025. This chart shows how BioCryst Pharmaceuticals Inc's Long-term Investment Intensity has evolved across 12 annual periods from 2011 to 2025. As of December 2025, the intensity stands at 11.9%, reflecting long-term investments of $61.16 Million against total assets of $514.16 Million USD. See how many days can BioCryst Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
BioCryst Pharmaceuticals Inc Long-term Investment Intensity by Year (2011–2025)
BioCryst Pharmaceuticals Inc long-term investment intensity by year from 2011 to 2025. The table below presents the year-by-year Long-term Investment Intensity for BioCryst Pharmaceuticals Inc from 2011 to 2025, covering 12 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see BioCryst Pharmaceuticals Inc balance sheet assets.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 11.9% | $61.16 Million | $514.16 Million | ▲ +7.8 pp |
| 2024 | 4.1% | $20.32 Million | $490.42 Million | ▲ +0.9 pp |
| 2022 | 3.3% | $18.08 Million | $550.00 Million | ▲ +2.1 pp |
| 2021 | 1.2% | $6.83 Million | $588.15 Million | ▼ -14.1 pp |
| 2018 | 15.2% | $22.38 Million | $146.84 Million | ▼ -7.9 pp |
| 2017 | 23.2% | $41.30 Million | $178.26 Million | ▲ +13.2 pp |
| 2016 | 9.9% | $8.93 Million | $89.85 Million | ▼ -28.3 pp |
| 2015 | 38.3% | $47.68 Million | $124.56 Million | ▲ +8.2 pp |
| 2014 | 30.0% | $41.12 Million | $136.87 Million | ▲ +24.8 pp |
| 2013 | 5.3% | $2.58 Million | $48.87 Million | ▲ +3.3 pp |
| 2012 | 2.0% | $1.15 Million | $57.44 Million | ▼ -16.7 pp |
| 2011 | 18.7% | $15.38 Million | $82.21 Million | — |